全球脓毒症诊断市场规模、份额、成长分析，按技术（血液培养技术和免疫测定）、按应用（医院和诊断中心）- 2024-2031 年行业预测

Global Sepsis Diagnostics Market Size, Share, Growth Analysis, By Technology(Blood Culture Technology and Immunoassays), By Application(Hospitals and Diagnostics Centres) - Industry Forecast 2024-2031

出版日期: 2024年03月23日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022 年全球脓毒症诊断市场规模为 6.7 亿美元，预计将从 2023 年的 7.4 亿美元增长到 2031 年的 15.5 亿美元，预测期内（2024-2031 年）复合年增长率为 9.8%。

世界卫生组织 (WHO) 报告称，败血症影响全球超过 3000 万人，每年导致 600 万人死亡，其中 300 万新生儿和 120 万儿童受到影响。脓毒症的高盛行率预计将增加对诊断解决方案的需求，从而推动脓毒症诊断市场的成长。目前脓毒症的诊断测试需要长达 72 小时才能提供最终结果，因此对快速诊断测试以实现早期诊断的需求很高。由于多种因素，脓毒症诊断解决方案市场预计在未来几年将快速成长。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 欧洲其他地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 拉丁美洲其他地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- MEA 的其余部分

竞争格局

前 5 名玩家比较
2021 年关键参与者的市场定位
主要市场参与者所采取的策略
最佳制胜策略
近期市集活动
主要公司市占率（%），2021年

主要公司简介

Abbott Laboratories (US)
Becton, Dickinson and Company (US)
bioMA(C)rieux SA (France)
Cepheid (US)
F. Hoffmann-La Roche AG (Switzerland)
Hologic Inc. (US)
Imbio LLC (US)
Luminex Corporation (US)
MedMira Inc. (Canada)
Meridian Bioscience, Inc. (US)
Nanosphere (US)
QIAGEN NV (Netherlands)
Thermo Fisher Scientific Inc. (US)
T2 Biosystems, Inc. (US)
Biomarck Pharmaceuticals Ltd. (UK)
Magnitude Biosciences (US)
Axis-Shield Diagnostics Ltd. (UK)
Biocartis Group NV (Belgium)
Inflammatix Inc. (US)
OpGen, Inc. (US)

简介目录

Product Code: SQMIG35A2237

Global Sepsis Diagnostics Market size was valued at USD 0.67 billion in 2022 and is poised to grow from USD 0.74 billion in 2023 to USD 1.55 billion by 2031, growing at a CAGR of 9.8% during the forecast period (2024-2031).

The World Health Organization (WHO) reports that sepsis affects over 30 million people worldwide and results in 6 million deaths annually, with 3 million newborns and 1.2 million children affected. The high prevalence of sepsis is expected to increase the demand for diagnostic solutions, which will drive the growth of the sepsis diagnostic market. The current diagnostic tests for sepsis take up to 72 hours to provide final results, making the demand for rapid diagnostic tests high for early diagnosis. The market for sepsis diagnostic solutions is expected to grow rapidly in the coming years due to a number of factors.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Sepsis Diagnostics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Sepsis Diagnostics Market Segmental Analysis

Worldwide Sepsis Market segments for diagnostics include type, application, and geography. The market can be divided into blood culture technology and immunoassays based on kind. The market is divided into diagnostic centers and hospitals based on application. The market is divided into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America based on geographic factors.

Drivers of the Global Sepsis Diagnostics Market

A major global health problem is the rising incidence of hospital-acquired infections (HAIs), also known as nosocomial infections. Pneumonia, sepsis, and urinary tract infections are some of the most common HAIs. Patients who are immunocompromised, old, or suffering from chronic conditions are among the susceptible patient populations where these infections can have very serious implications. With an annual increase of 8.7%, there is a concerning trend in the United States about the increased frequency of sepsis among hospitalized patients. As to the Centers for Disease Control and Prevention (CDC) data from 2018, the number of hospitalized patients in the United States who experience sepsis annually is anticipated to be over 1,000,000.

Restraints in the Global Sepsis Diagnostics Market

The high cost of developing and introducing into the market cutting-edge diagnostic solutions is one of the main obstacles to the global sepsis diagnostic industry. Furthermore, the general public's ignorance of sepsis and its symptoms may be impeding the market's expansion. Additionally, the availability of sepsis diagnostic technologies may be restricted in poorer nations due to a lack of healthcare infrastructure, which could impede market expansion. The strict regulatory structure that controls diagnostic solution approval might also provide difficulties for market-based producers.

Market Trends of the Global Sepsis Diagnostics Market

An important development in the global market for sepsis diagnostics is the growing use of point-of-care (POC) testing. POC tests are intended to diagnose sepsis quickly and precisely, which can greatly enhance patient outcomes. POC tests are perfect for use in emergency rooms, ambulances, and critical care units since they are portable, simple to use, and can be carried out outside of the conventional laboratory setting. Over the course of the projection period, there will likely be a rise in demand for POC testing due to the growing acceptance of digital health technologies and the necessity for quick diagnosis.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Sepsis Diagnostics Market by Technology

Market Overview
Blood Culture Technology and Immunoassays

Global Sepsis Diagnostics Market by Application

Market Overview
Hospitals and Diagnostics Centres

Global Sepsis Diagnostics Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Abbott Laboratories (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
bioMA(C)rieux SA (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cepheid (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hologic Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Imbio LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Luminex Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MedMira Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Meridian Bioscience, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nanosphere (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QIAGEN N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
T2 Biosystems, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biomarck Pharmaceuticals Ltd. (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Magnitude Biosciences (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Axis-Shield Diagnostics Ltd. (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocartis Group NV (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Inflammatix Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
OpGen, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments